List of Excipients in Branded Drug AUROVELA 1/20

« Back to Dashboard

Generic Drugs Containing AUROVELA 1/20

Company	Ingredient	NDC	Excipient
Aurobindo Pharma Limited	norethindrone acetate and ethinyl estradiol	65862-939	.ALPHA.-TOCOPHEROL
Aurobindo Pharma Limited	norethindrone acetate and ethinyl estradiol	65862-939	CELLULOSE, MICROCRYSTALLINE
Aurobindo Pharma Limited	norethindrone acetate and ethinyl estradiol	65862-939	CROSCARMELLOSE SODIUM
Aurobindo Pharma Limited	norethindrone acetate and ethinyl estradiol	65862-939	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in AUROVELA 1/20?

# Of NDCs	Excipient
1	.ALPHA.-TOCOPHEROL
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	D&C YELLOW NO. 10

Aurovela 1/20 Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Aurovela 1/20 is a low-dose combined oral contraceptive containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg per active tablet. Its commercial opportunity is primarily in cost-efficient generic manufacturing, differentiated packaging, tolerability-oriented excipient design, and portfolio extensions rather than molecule-level patent protection. The core formulation uses conventional excipients, leaving room for improvements in tablet robustness, dissolution consistency, swallowability, packaging, and patient adherence. [1]

What is Aurovela 1/20?

Aurovela 1/20 is an oral contraceptive marketed under an abbreviated new drug application. Each active tablet contains:

Attribute	Aurovela 1/20
Norethindrone acetate	1 mg
Ethinyl estradiol	20 mcg
Dosage form	Immediate-release oral tablet
Therapeutic category	Combined hormonal contraceptive
Regulatory pathway	FDA ANDA
Manufacturer/labeler	Aurobindo Pharma Limited
Typical regimen	21 active tablets, followed by a hormone-free interval
Drug class	Progestin plus estrogen

Aurovela 1/20 is distinct from Aurovela Fe 1/20, which adds ferrous fumarate tablets to the pack. The “Fe” product creates a separate packaging and formulation opportunity because the iron tablets are nonhormonal and require control of elemental iron content, tablet color, dissolution, and pack sequencing. [1]

What excipients are used in Aurovela 1/20?

The public product labeling identifies conventional oral-tablet excipients, including lactose monohydrate, magnesium stearate, povidone, pregelatinized starch, and talc. The tablets also contain permitted colorants or coating components where applicable. [1]

Excipient or excipient class	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and tablet bulk	Low cost, strong manufacturing history; restricts lactose-free positioning
Pregelatinized starch	Binder and disintegrant	Supports compression and tablet breakup
Povidone	Binder	Improves granule or tablet cohesion
Magnesium stearate	Lubricant	Controls ejection force; excessive levels can slow dissolution
Talc	Glidant or anti-adherent	Supports powder flow and manufacturing efficiency
Colorants/coating materials	Identification and appearance	Important for blister-pack differentiation and product recognition

The excipient system is not technically novel. Its value lies in balancing manufacturability, dissolution, content uniformity, stability, and cost.

How can the excipient formulation be improved?

The strongest development strategy is a controlled reformulation that preserves the active ingredients, dose, immediate-release profile, and bioequivalence while improving manufacturing or patient-use characteristics.

Lactose reduction or replacement

Lactose is a low-cost diluent with broad use in oral solid dosage forms. A lactose-free version could target patients who avoid lactose or who prefer simpler excipient declarations. Candidate replacements include microcrystalline cellulose, mannitol, dibasic calcium phosphate, or combinations of these materials.

Each substitute changes powder flow, compressibility, moisture behavior, tablet hardness, and disintegration. Calcium phosphate can improve mechanical strength but may alter dissolution and create a denser tablet. Mannitol can improve mouthfeel but may increase cost. Microcrystalline cellulose can improve compactibility and reduce reliance on a separate binder.

A lactose-free version would have commercial value only if the excipient change produces a meaningful purchasing or prescribing advantage. The product would still need to meet applicable ANDA requirements and demonstrate comparable quality and bioequivalence.

Low-magnesium-stearate lubrication

Magnesium stearate is effective but can create dissolution problems when over-lubrication occurs. A refined blending and lubrication process could reduce hydrophobic coating of particles and improve batch-to-batch dissolution consistency.

Potential approaches include:

• Lowering magnesium stearate concentration.
• Shortening lubrication time.
• Using a controlled addition sequence.
• Evaluating sodium stearyl fumarate or another alternative lubricant.
• Establishing a tighter process control strategy for blend uniformity and tablet ejection force.

This opportunity is primarily manufacturing-focused. It is more likely to support cost reduction and quality consistency than premium pricing.

Direct-compression platform

A direct-compression formulation could reduce processing steps by eliminating wet granulation or other intermediate operations. The active ingredients are present at low dose, particularly ethinyl estradiol, so content uniformity is the key technical challenge.

A direct-compression platform would require careful control of:

• API particle-size distribution.
• Ordered mixing or carrier-based distribution.
• Segregation during transfer.
• Blend sampling and assay.
• Tablet weight variation.
• Content uniformity.
• Dissolution at multiple pH conditions.

The low ethinyl estradiol dose increases the commercial value of a robust content-uniformity process. A manufacturer that can reduce rejected batches, improve yield, and simplify equipment may achieve a lower cost of goods.

Smaller or easier-to-swallow tablet

Aurovela 1/20 contains a low mass of active ingredients, but the excipients determine tablet size. A smaller tablet could improve adherence, especially for users who experience difficulty swallowing tablets.

Possible approaches include higher-density fillers, optimized compression, reduced coating weight, and more efficient excipient selection. The commercial benefit is credible, but tablet size cannot be reduced at the expense of friability, dissolution, content uniformity, or packaging protection.

Dye and colorant strategy

A colorant-free or reduced-colorant version could appeal to patients avoiding specific dyes. Colorants also create an opportunity for product identification, particularly where tablets are packaged in calendar blisters.

The main limitations are operational. Color changes may require new specifications, stability work, label updates, and additional human-factors review because contraceptive packs depend on correct tablet sequencing.

What formulation patents protect Aurovela 1/20?

Aurovela 1/20 is a generic product, and its principal commercial protection does not arise from a proprietary excipient platform. Public product labeling identifies the formulation and regulatory status but does not identify an active Orange Book patent estate for Aurovela 1/20 itself. [1,2]

IP category	Relevance to Aurovela 1/20
API composition patent	Not a meaningful barrier for this established combination
Core formulation patent	No public proprietary formulation protection identified in the product label
Excipient patent	Conventional excipients provide limited defensibility
Method-of-use patent	Contraceptive use is established and commercially generic
Manufacturing patent	Process know-how may be protectable if genuinely novel
Packaging or adherence patent	Possible, especially for dispensing systems or connected packaging
Trademark	Aurovela brand name is commercially relevant but does not block equivalent generics

A new excipient system could support patent protection only if it produces a non-obvious technical result, such as an unexpected stability improvement, a distinct dissolution profile with clinical or manufacturing value, or a specific compatibility solution. Simply replacing lactose with microcrystalline cellulose would usually provide weak patent positioning.

When does Aurovela 1/20 lose exclusivity?

Aurovela 1/20 is already marketed as a generic under the FDA ANDA pathway. The relevant commercial question is therefore not the loss of an originator exclusivity period, but the level of competition among ANDA holders and authorized distributors.

The FDA Orange Book records approved drug products and, where applicable, patent and exclusivity information associated with listed products. Generic oral contraceptives generally face competition based on price, supply reliability, distributor access, and formulary placement rather than remaining molecule-level exclusivity. [2]

No biosimilar pathway applies. Aurovela 1/20 is a small-molecule tablet, not a biologic. Competitive products are approved through ANDAs or other small-molecule pathways, not abbreviated biosimilar applications.

Are Paragraph IV challenges relevant to Aurovela 1/20?

Paragraph IV litigation is unlikely to be the primary risk for an established generic Aurovela 1/20 product. Paragraph IV certifications matter when an ANDA applicant challenges an unexpired patent listed for a reference drug. For a mature norethindrone acetate and ethinyl estradiol tablet, competition is more likely to involve ordinary ANDA approval, manufacturing transfer, product discontinuation, or supply disruptions.

A Paragraph IV strategy could become relevant if a company develops:

• A novel extended-cycle presentation.
• A distinct delivery system.
• A new combination involving the same hormones.
• A formulation claiming improved stability or controlled release.
• A packaging system with a potentially patentable adherence function.

These products would face a different regulatory and IP analysis from a standard Aurovela 1/20 equivalent.

What FDA regulatory issues apply to excipient changes?

A formulation change to an approved generic product must be managed through the ANDA postapproval framework. The filing route depends on the scale and effect of the change. FDA guidance distinguishes changes that can be handled through annual reporting, changes requiring a prior approval supplement, and changes requiring other postapproval submissions. [3]

For an excipient reformulation, the development package should address:

1. Comparative dissolution against the approved product.
2. Assay and content uniformity, with particular attention to ethinyl estradiol.
3. Tablet hardness, friability, disintegration, and weight variation.
4. Stability under long-term and accelerated conditions.
5. Impurity and degradation-product profiles.
6. Manufacturing process validation.
7. Bioequivalence where the change could affect absorption.
8. Updated labeling and inactive-ingredient declarations.
9. Drug Master File or supplier qualification documentation where applicable.

Excipient suppliers should be evaluated for compendial compliance, supply continuity, residual solvents, elemental impurities, microbial quality, and change-control discipline. A low-cost excipient with unstable supply or frequent specification changes can create greater commercial risk than a higher-priced material from a qualified supplier.

What commercial opportunities exist for excipient suppliers?

The most attractive opportunities are platform-based rather than Aurovela-specific.

Lactose-free contraceptive platform

An excipient supplier could develop a directly compressible lactose-free platform optimized for low-dose hormonal APIs. The value proposition would combine:

• Improved blend uniformity.
• Low tablet mass.
• Strong mechanical properties.
• Rapid immediate-release dissolution.
• Lower segregation risk.
• Compatibility with high-speed tablet presses.

This platform could extend beyond Aurovela 1/20 to other low-dose contraceptives, antihypertensives, and endocrine products.

High-content-uniformity low-dose platform

Ethinyl estradiol is present at 20 mcg per active tablet. A specialized carrier or co-processing system that improves distribution of microgram-level API could support multiple products. The strongest commercial claim would be reduced content-uniformity variability and improved manufacturing yield.

Calendar-blister and adherence packaging

Packaging is a higher-value differentiation route than excipient substitution alone. A manufacturer could combine a conventional formulation with:

• Day-labeled blister cards.
• Tactile tablet sequencing.
• Color-coded active-tablet identification.
• Unit-dose moisture protection.
• Refill reminders.
• Serialization and adherence-tracking features.

Packaging improvements may support private-label contracts and payer or pharmacy-channel differentiation without changing the active formulation.

Aurovela Fe 1/20 extension

Aurovela Fe 1/20 creates a product-line opportunity involving iron-containing reminder tablets. A manufacturer could compete through pack design, reduced tablet breakage, optimized iron tablet color, improved moisture protection, and calendar labeling.

The technical risk is higher than for a plain 21-tablet product because the packaging must prevent confusion between active hormonal tablets and nonhormonal iron tablets.

How strong is the patent estate for Aurovela 1/20?

The patent estate is weak for a standard generic formulation. The principal defensible assets are more likely to be:

• Manufacturing process controls.
• Proprietary excipient combinations.
• Supplier agreements.
• Packaging designs.
• Brand recognition.
• Distribution contracts.
• Regulatory execution.
• Stable product availability.

A conventional excipient substitution is unlikely to create durable exclusivity. A stronger strategy would protect a specific technical result with a layered portfolio covering formulation composition, manufacturing process, packaging, and product-line extensions.

What generic entry risks exist?

Generic-entry risk is already embedded in the product category. The main risks are commercial:

Risk	Potential effect
Price erosion	Lower net sales and reduced distributor margins
Multiple ANDA suppliers	Increased substitution and tender pressure
Manufacturing interruption	Stockouts and loss of pharmacy placement
API supply concentration	Cost volatility and delayed production
Quality failure	Recalls, warning letters, or customer loss
Pack confusion	Incorrect use of active or reminder tablets
Formulary exclusion	Reduced prescription volume
Product discontinuation	Loss of market continuity and wholesaler confidence

For a generic contraceptive, reliable supply can be more valuable than a minor excipient innovation. Pharmacy buyers and wholesalers often prioritize availability, approved packaging, competitive pricing, and predictable lead times.

How does Aurovela 1/20 compare with competing products?

Product type	Active ingredients	Commercial distinction
Aurovela 1/20	Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg	Standard generic 21-tablet formulation
Aurovela Fe 1/20	Same hormones plus ferrous fumarate reminder tablets	28-tablet pack with iron tablets
Other norethindrone/ethinyl estradiol generics	Same or closely related strengths	Price, supplier reliability, packaging
Drospirenone/ethinyl estradiol products	Different progestin	Different clinical and commercial profile
Levonorgestrel/ethinyl estradiol products	Different progestin	Broad generic competition
Progestin-only pills	No estrogen	Different patient and safety positioning

Aurovela 1/20 competes in a crowded category. Excipient differentiation is unlikely to win the market alone. The strongest combination is reliable supply, competitive cost, low-dose manufacturing expertise, and adherence-oriented packaging.

What licensing deals are relevant?

There is no clear licensing opportunity in the standard Aurovela 1/20 formulation based solely on its listed conventional excipients. Licensing value could arise from:

• A patented low-dose blending technology.
• A co-processed excipient system.
• A moisture-protective blister technology.
• A digital adherence platform.
• A novel extended-cycle regimen.
• A reformulation with a demonstrated tolerability or stability advantage.

A license should be evaluated against the limited pricing power of a generic oral contraceptive. Royalty-bearing excipient technology must reduce manufacturing cost, improve approval probability, or create a differentiated channel position.

Key Takeaways

• Aurovela 1/20 contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
• Its listed excipients are conventional, including lactose monohydrate, pregelatinized starch, povidone, magnesium stearate, and talc.
• The product has limited molecule-level patent defensibility because it is an established generic.
• The best excipient opportunities are lactose-free design, direct compression, improved low-dose content uniformity, and optimized lubrication.
• Packaging and adherence systems offer greater commercial differentiation than basic excipient replacement.
• Aurovela Fe 1/20 provides a separate product-line opportunity involving ferrous fumarate reminder tablets.
• Biosimilar risk does not apply because Aurovela 1/20 is a small-molecule oral tablet.
• Generic competition is driven by price, supply reliability, manufacturing quality, wholesaler access, and formulary position.
• Any postapproval excipient change must be assessed under FDA ANDA supplement and bioequivalence requirements.

FAQs

Can Aurovela 1/20 be made lactose-free?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed excipient. The reformulated product would need to maintain content uniformity, dissolution, stability, and bioequivalence requirements.

Is Aurovela 1/20 a biologic or biosimilar product?

No. Aurovela 1/20 is a small-molecule combination tablet approved through the ANDA pathway. Biosimilar competition does not apply.

Does Aurovela 1/20 have a proprietary excipient patent?

The public product label identifies conventional excipients and does not establish a proprietary excipient patent position for the marketed product. Any new formulation would require a separate patent and regulatory analysis.

What is the main manufacturing challenge for Aurovela 1/20?

The main technical challenge is uniform distribution of the very low ethinyl estradiol dose, together with consistent norethindrone acetate assay, tablet weight, dissolution, and blend segregation control.

Is Aurovela Fe 1/20 a separate commercial opportunity?

Yes. Aurovela Fe 1/20 adds ferrous fumarate reminder tablets and uses a different 28-tablet packaging configuration. It creates opportunities in packaging, tablet identification, moisture control, and adherence design.

References

1. DailyMed. (n.d.). Aurovela 1/20: Norethindrone acetate and ethinyl estradiol tablets, USP prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2004). Changes to an approved NDA or ANDA: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/changes-approved-nda-or-anda